Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines: World Health Organization consultations, October 2021-March 2022.
Prudden HJ, Achilles SL, Schocken C, Broutet N, Canfell K, Akaba H, Basu P, Bhatla N, Chirenje ZM, Delany-Moretlwe S, Denny L, Gamage DG, Herrero R, Hutubessy R, Villa LL, Murillo R, Schiller JT, Stanley M, Temmerman M, Zhao F, Ogilvie G, Kaslow DC, Dull P, Gottlieb SL; Therapeutic HPV Vaccine PPC Expert Consultation Group*.
Prudden HJ, et al. Among authors: temmerman m.
Vaccine. 2022 Sep 29;40(41):5843-5855. doi: 10.1016/j.vaccine.2022.08.020. Epub 2022 Aug 22.
Vaccine. 2022.
PMID: 36008233